The biotech sector performed well in August, with the iShares Nasdaq Biotechnology ETF ( IBB ) up almost 3.5% this week alone. Research by Raymond James indicates that in just the past week, biotech funds saw $510 million in capital inflows. This in part led major biotech companies like Biogen Inc ( BIIB ) and Celgene Corp (NASDAQ: [...] Read more on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
This article was provided by our partner Tom Lydon of etftrends.com.